DRNA Shares Outstanding History



Below is a table of the DRNA shares outstanding history going back to 1/30/2014:

Date DRNA Shares Outstanding
1/30/201415.63M
3/26/201417.76M
5/9/201417.76M
8/5/201417.77M
11/5/201417.77M
3/11/201517.82M
5/8/201517.83M
8/5/201520.59M
11/10/201520.59M
3/9/201620.65M
5/6/201620.73M
8/2/201620.75M
11/4/201620.75M
3/29/201720.79M
3/31/201720.79M
5/5/201720.79M
8/9/201720.84M
11/1/201720.85M
3/7/201851.77M
5/11/201852.82M
8/6/201852.95M
11/2/201862.73M
3/4/201968.26M
5/6/201968.32M
8/5/201968.36M
7/26/2019256.66M
11/4/201968.43M
2/24/202073.75M
4/30/202073.92M
7/31/202074.46M
11/2/202075.04M
2/22/202176.32M
4/30/202176.90M
8/2/202177.73M
11/4/202177.89M

Also see: DRNA Market Cap History
DRNA YTD Return
DRNA Historical Shares Outstanding:
+22.98% CAGR
DRNA Historical Shares Outstanding: +22.98% CAGR

Mouse over chart for data details
1/30/2014 ...11/4/2021
Dicerna Pharmaceuticals is a biopharmaceutical company focused on discovering, developing, and commercializing medicines that are designed to utilize ribonucleic acid interference to silence selectively genes that cause or contribute to disease. Nedosiran is Co.'s investigational product candidate for the treatment of primary hyperoxaluria (PH) type 1, PH type 2, and PH type 3. Co.'s GalXC product candidate, RG6346, is for the treatment of chronic hepatitis B virus (HBV) infection. Therapies for HBV include nucleoside analogs and pegylated interferon regimens. Co.'s another GalXC product candidate, belcesiran, is for the treatment of alpha-1 antitrypsin deficiency-associated liver disease. We show 35 historical shares outstanding datapoints in our coverage of DRNA's shares outstanding history.

Understanding the changing numbers of DRNA shares outstanding — and comprehending the concept of differing number of shares outstanding in general comparing companies like DRNA versus peers — is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies. Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history. With this page we aim to empower investors researching DRNA by allowing them to research DRNA shares outstanding history as well as any other stock in our coverage universe.
Quotes delayed 20 minutes

Email EnvelopeFree DRNA Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Shares Outstanding Importance


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Dicerna Pharmaceuticals (DRNA) is categorized under the Healthcare sector; to help you further research historical shares outstanding numbers, below are some other companies in the same sector:

DRRX Shares Outstanding History
DSGN Shares Outstanding History
DTIL Shares Outstanding History
DVA Shares Outstanding History
DVAX Shares Outstanding History
DVCR Shares Outstanding History
DXCM Shares Outstanding History
DYAI Shares Outstanding History
DYN Shares Outstanding History
DYNT Shares Outstanding History
More Healthcare companies »

 

DRNA Shares Outstanding History | www.SharesOutstandingHistory.com | Copyright © 2017 - 2024, All Rights Reserved

Nothing in SharesOutstandingHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
X
Wait! Don't leave yet.
Want to receive our latest research absolutely free?


Click the button below for your complimentary copy of Your Early Retirement Portfolio: Dividends Up to 9.5%—Every Month—Forever.

You'll discover the details on 4 stocks and funds that pay you massive dividends as high as 9.5%.